Solvay Pharmaceuticals B.V.

Ion-strength independent sustained release pharmaceutical formulation

Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition

Process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one and salts and solvates thereof

Combination preparations comprising SLV308 and a dopamine agonist

Sulphur containing pyrazole derivatives as selective cannabinoid CB receptor antagonists

1H-imidazole derivative having CB, agonistic, CBpartial agonistic or CBantagnistic activity

4,5-dihydro-1H-pyrazole derivatives having CB-antagonistic activity

5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists

Embedded micellar nanoparticles

Heterocyclic compounds with affinity to muscarinic receptors

N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs

4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CBreceptor modulators

Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HTantagonists

Bifeprunox mesylate maintenance dose compositions and methods for using the same

Compounds with a combination of cannabinoid CBantagonism and serotonin reuptake inhibition

Compounds with a combination of cannabinoid-CBantagonism and acetylcholinesterase inhibition

4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7H-pyrrolo [2,3D] pyrimidine hydrogen mesylate, its polymorphic forms, and methods for making same

1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CBreceptor agonistic, partial agonistic, inverse agonistic or antagonistic activity

Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition

Combination preparations comprising bifeprunox and a dopamine agonist

Combination preparations comprising SLV308 and a dopamine agonist

1,3,5-Triazine derivatives as ligands for human adenosine-A3 receptors

Sulphur containing pyrazole derivatives as selective cannabinoid CBreceptor antagonists

4,5-dihydro-1H-pyrazole derivatives having potent CB-antagonistic activity

Glucuronate salt of a piperazine compound

Screening and treatment methods using IGS5 enzymes of the metalloprotease family

Antibody to human enzymes of the metalloprotease family

Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-Dreceptors and serotonin reuptake sites

Sustained-release formulation and uses thereof

Neurotensin active 2,3,diaryl-pyrazolidine derivatives

N-oxides as prodrugs of piperazine and piperidine derivatives

Imidazoline derivatives having CB-antagonistic activity

Human enzymes of the metalloprotease family

[1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular

Piperazine oxime dervatives having NK-1 receptor antagonistic activity

Human enzymes of the metalloprotease family

Phenylpiperazines

Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-Dreceptors and serotonin reuptake sites

Phenylpiperazine derivatives with a combination of partial dopamine-Dreceptor agonism and serotonin reuptake inhibition

Mesylates of piperazine derivatives and process for their preparation

Process for preparation of imidazolyl compounds

2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity

2-substituted-6-trifluoromethyl purine derivatives with adenosine-Aantagonistic activity

4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity

Tetrasubstituted imidazole derivatives as cannabinoid CB receptor modulators with a high CB/CBreceptor subtype selectivity

Binding assay employing IGS4, a human G-protein coupled neuromedin receptor

8-{4-[3-(5-fluoro-1H-indol-3-YL)-Propyl]-Piperazin-1-YL}-2-methyl-4H-Benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site

Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds

Process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one and salts and solvates thereof

8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine Dreceptor and the serotonin reuptake site

Compounds and their use in therapy

1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity

Piperazine and piperidine compounds

Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors

Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NKantagonistic activity

Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors

Compounds and their use in therapy

Solid salts of benzazepine compounds and pharmaceutical compositions containing them

Human enzymes of the metalloprotease family

Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds